Skip to main
MGTX

MGTX Stock Forecast & Price Target

MGTX Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MeiraGTx Holdings is a vertically integrated, clinical-stage genetic medicines company with strong in-house manufacturing capabilities and proprietary platforms, focusing on high unmet need diseases such as radiation-induced xerostomia and rare inherited retinal dystrophy. The company's large potential in the market is supported by strong clinical data, with opportunities for non-dilutive financing and partnerships with companies like Hologen AI. Management has also taken steps towards sustainability and diversity, which could positively impact long-term growth and productivity. Despite some variability in patient response, the data so far supports the company's ability to have a lasting effect on patients, adding to the positive outlook for this biotech company.

Bears say

MeiraGTx Holdings is currently a high-risk investment due to their dependence on clinical program execution, regulatory uncertainties, and potential competition in the market for diseases such as XLRP and Parkinson's. Their recent acquisition of the XLRP program may provide a potential for future revenue, but it remains uncertain and carries financial and regulatory risks. Additionally, the company's focus on genetic medicines may face long-term pricing pressure, making it a risky investment choice in the long run.

MGTX has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MeiraGTx Holdings plc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MeiraGTx Holdings plc (MGTX) Forecast

Analysts have given MGTX a Strong Buy based on their latest research and market trends.

According to 7 analysts, MGTX has a Strong Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MeiraGTx Holdings plc (MGTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.